Broadly protective multivalent OspA vaccine against lyme borreliosis, developed based on surface shaping of the C-terminal fragment

Abhijeet Nayak, Wolfgang Schüler, Stefan Seidel, Ivan Gomez, Andreas Meinke, P. r Comstedt, Urban Lundberg

Research output: Contribution to journalArticleAcademicpeer-review

23 Citations (Scopus)


The development of vaccines for prevention of diseases caused by pathogenic species can encounter major obstacles if high sequence diversity is observed between individual strains. Therefore, development might be restricted either to conserved antigens, which are often rare, or to multivalent vaccines, which renders the production more costly and cumbersome. In light of this complexity, we applied a structure-based surface shaping approach for the development of a Lyme borreliosis (LB) vaccine suitable for the United States and Europe. The surface of the C-terminal fragment of outer surface protein A (OspA) was divided into distinct regions, based primarily on binding sites of monoclonal antibodies (MAbs). In order to target the six clinically most relevant OspA serotypes (ST) in a single protein, exposed amino acids of the individual regions were exchanged to corresponding amino acids of a chosen OspA serotype. Six chimeric proteins were constructed, and, based on their immunogenicity, four of these chimeras were tested in mouse challenge models. Significant protection could be demonstrated for all four proteins following challenge with infected ticks (OspA ST1, OspA ST2, and OspA ST4) or with in vitro-grown spirochetes (OspA ST1 and OspA ST5). Two of the chimeric proteins were linked to form a fusion protein, which provided significant protection against in vitro-grown spirochetes (OspA ST1) and infected ticks (OspA ST2). This article presents the proof-of-concept study for a multivalent OspA vaccine targeting a wide range of pathogenic LB Borrelia species with a single recombinant antigen for prevention of Lyme borreliosis.
Original languageEnglish
Article numbere00917-19
JournalInfection and Immunity
Issue number4
Publication statusPublished - 1 Apr 2020


  • Borrelia
  • Lyme
  • OspA
  • Vaccine

Cite this